Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Imaxen 100 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Imatinib. It is listed here as a same-ingredient branded option for people researching Gleevec / Glivec, a reference brand associated with Novartis. Imaxen and Gleevec / Glivec must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 100 mg strength.
Imaxen vs. Gleevec / Glivec – Originator / Reference Brand Comparison
Gleevec / Glivec is a widely recognized reference brand for Imatinib associated with Novartis. Imaxen is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Imaxen is manufactured by Novartis, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Imatinib
Strength: 100 mg
Dosage form: Tablet
Pharmacological class: BCR-ABL/KIT/PDGFR kinase inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Imatinib is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Imatinib Works
Imatinib is a BCR-ABL/KIT/PDGFR kinase inhibitor. In general, it blocks BCR-ABL, KIT and PDGFR signaling. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 100 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Imatinib include: fluid retention, low blood counts and liver injury. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Imatinib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include fluid retention, low blood counts and liver injury. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Imatinib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Imatinib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Imaxen Listed as an Alternative to Gleevec / Glivec?
This listing helps customers identify an Everest Pharmaceuticals product containing Imatinib while researching Gleevec / Glivec. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Imaxen
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Gleevec / Glivec
Reference company: Novartis
Generic ingredient: Imatinib
Strength: 100 mg
Dosage form: Tablet
Therapeutic class: BCR-ABL/KIT/PDGFR kinase inhibitor
Frequently Asked Questions
What is Imaxen 100 mg?
It is an Everest Pharmaceuticals tablet containing Imatinib 100 mg.
Is Imaxen the same as Gleevec / Glivec?
They are presented as brands associated with Imatinib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Imatinib used for?
Imatinib is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings, subject to the applicable label and clinical assessment.
How does Imatinib work?
It blocks BCR-ABL, KIT and PDGFR signaling.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Imatinib |
|---|---|
| Strength | 100 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 30 tablets |
Related products
Alecensa 150 mg Alternative – Alecnib (Alectinib) 150 mg Capsule | Everest Pharmaceuticals
Alecnib 150 mg (Alectinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Alecensa (Roche / Genentech). It belongs to the ALK inhibitor class and is used in appropriately tested ALK-positive non-small cell lung cancer.
Active ingredient: Alectinib
Strength: 150 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Avastin 400 mg Alternative – Bevixa (Bevacizumab) 400 mg IV infusion | Incepta Pharmaceuticals
Bevixa 400 mg (Bevacizumab) IV infusion is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Avastin (Roche).
Pack: 1 vial. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Erleada 60 mg Alternative – Prostaxen (Apalutamide) 60 mg Tablet | Everest Pharmaceuticals
Prostaxen 60 mg (Apalutamide) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Erleada (Janssen). It belongs to the androgen receptor inhibitor class and is used in selected castration-resistant or castration-sensitive prostate cancer settings.
Active ingredient: Apalutamide
Strength: 60 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Osimert (Osimertinib) 80 mg Tablet | Everest Pharmaceuticals
Osimert 80 mg (Osimertinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tagrisso (AstraZeneca). It belongs to the EGFR tyrosine kinase inhibitor class and is used in selected EGFR-mutated non-small cell lung cancer.
Active ingredient: Osimertinib
Strength: 80 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tukysa 150 mg Alternative – Tucaxen (Tucatinib) 150 mg Tablet | Everest Pharmaceuticals
Tucaxen 150 mg (Tucatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tukysa (Seagen / Pfizer). It belongs to the HER2 tyrosine kinase inhibitor class and is used in selected HER2-positive breast cancer treatment combinations.
Active ingredient: Tucatinib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Votrient 200 mg Alternative – Pazorest (Pazopanib) 200 mg Tablet | Everest Pharmaceuticals
Pazorest 200 mg (Pazopanib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Votrient (Novartis). It belongs to the multitarget kinase inhibitor class and is used in selected advanced renal cell carcinoma and soft tissue sarcoma.
Active ingredient: Pazopanib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.